Haemonetics Corporation (HAE)

NYQ – Real Time Price. Currency in USD

77.29

-0.33 (-0.43%)

At close: Jun 26, 2026, 4:00 PM EDT

78.33

+1.04 (1.35%)

After-hours: Jun 26, 2026, 5:05 PM EDT

11.06.2026

Pharvaris Announces Annual General Meeting of Shareholders

ZUG, Switzerland, June 11, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced the annual general meeting of shareholders will take place on Friday, June 26, 2026, at 16:00 CEST (10:00 a.m. EDT).

08.06.2026

Haemonetics Corporation (HAE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

05.06.2026

Haemonetics Updates Financial Reporting Segments

BOSTON, June 5, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative solutions designed to improve patient outcomes, today announced an update to its reportable segment structure to better align external financial reporting with how the Company manages its business and allocates resources. Under the new structure, Haemonetics will transition from three reportable segments to two.

02.06.2026

Haemonetics to Present at Goldman Sachs 47th Annual Global Healthcare Conference

BOSTON, June 2, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that Chris Simon, President and CEO, will participate in a fireside chat with investors at the Goldman Sachs 47th Annual Global Healthcare Conference on Monday, June 8, 2026 at 4:00 p.m. ET. The public may access a live webcast of the fireside chat at Haemonetics' Investor Relations website or at the following link: https://event.webcasts.com/starthere.jsp?ei=1766065&tp_key=0b16b4b62d&tp_special=8 A replay of the recorded webcast will become accessible 12 hours after the event and will be available for 90 days on Haemonetics' Investor Relations website.

22.05.2026

Investing in Haemonetics (HAE)? Don't Miss Assessing Its International Revenue Trends

Examine the evolution of Haemonetics' (HAE) overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects.

13.05.2026

Is the Options Market Predicting a Spike in Haemonetics Stock?

Investors need to pay close attention to GBTG stock based on the movements in the options market lately.

12.05.2026

Haemonetics Corporation (HAE) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Videos

No Data

There is no data to display

Haemonetics Corporation Announces Fourth Quarter Fiscal 2026 Financial Results Available on Investor Relations Website

Financial release and supplemental presentation accessible online BOSTON, May 7, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that financial results for its fourth quarter fiscal year 2026, which ended March 28, 2026, are available on the Company's Investor Relations website at www.haemonetics.com. The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m.

24.04.2026

New Study Highlights Safety and Efficacy Profile of Haemonetics' VASCADE MVP® XL in Large-Bore Venous Access Closure Procedures

BOSTON, April 24, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative solutions designed to improve patient outcomes, today announced the publication of a new study comparing its VASCADE MVP® XL vascular closure system with the VASCADE MVP® venous vascular closure system in the context of large‐bore venous access closure procedures. This study, "VASCADE MVP-XL Versus VASCADE MVP for Large-Bore Venous Access-Site Closure in Electrophysiology Procedures: A Single-Center Experience on Efficacy and Complications," was published earlier this week in the Journal of Cardiovascular Electrophysiology.

Haemonetics Corporation (HAE)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Haemonetics Corporation (HAE)

Pharvaris Announces Annual General Meeting of Shareholders

Haemonetics Corporation (HAE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Haemonetics Updates Financial Reporting Segments

Haemonetics to Present at Goldman Sachs 47th Annual Global Healthcare Conference

Investing in Haemonetics (HAE)? Don't Miss Assessing Its International Revenue Trends

Is the Options Market Predicting a Spike in Haemonetics Stock?

Haemonetics Corporation (HAE) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Videos

No Data

Press releases

Pharvaris Announces Annual General Meeting of Shareholders

Haemonetics Updates Financial Reporting Segments

Haemonetics Corporation Announces Fourth Quarter Fiscal 2026 Financial Results Available on Investor Relations Website

New Study Highlights Safety and Efficacy Profile of Haemonetics' VASCADE MVP® XL in Large-Bore Venous Access Closure Procedures

Pharvaris Announces Annual General Meeting of Shareholders

Haemonetics Corporation (HAE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Haemonetics Updates Financial Reporting Segments

Haemonetics to Present at Goldman Sachs 47th Annual Global Healthcare Conference

Investing in Haemonetics (HAE)? Don't Miss Assessing Its International Revenue Trends

Is the Options Market Predicting a Spike in Haemonetics Stock?

Haemonetics Corporation (HAE) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Videos

No Data

Press releases

Pharvaris Announces Annual General Meeting of Shareholders

Haemonetics Updates Financial Reporting Segments

Haemonetics Corporation Announces Fourth Quarter Fiscal 2026 Financial Results Available on Investor Relations Website

New Study Highlights Safety and Efficacy Profile of Haemonetics' VASCADE MVP® XL in Large-Bore Venous Access Closure Procedures

Search stocks

Haemonetics Corporation (HAE)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Haemonetics Corporation (HAE)

Pharvaris Announces Annual General Meeting of Shareholders

Haemonetics Corporation (HAE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Haemonetics Updates Financial Reporting Segments

Haemonetics to Present at Goldman Sachs 47th Annual Global Healthcare Conference

Investing in Haemonetics (HAE)? Don't Miss Assessing Its International Revenue Trends

Is the Options Market Predicting a Spike in Haemonetics Stock?

Haemonetics Corporation (HAE) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Videos

No Data

Press releases

Pharvaris Announces Annual General Meeting of Shareholders

Haemonetics Updates Financial Reporting Segments

Haemonetics Corporation Announces Fourth Quarter Fiscal 2026 Financial Results Available on Investor Relations Website

New Study Highlights Safety and Efficacy Profile of Haemonetics' VASCADE MVP® XL in Large-Bore Venous Access Closure Procedures

Pharvaris Announces Annual General Meeting of Shareholders

Haemonetics Corporation (HAE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Haemonetics Updates Financial Reporting Segments

Haemonetics to Present at Goldman Sachs 47th Annual Global Healthcare Conference

Investing in Haemonetics (HAE)? Don't Miss Assessing Its International Revenue Trends

Is the Options Market Predicting a Spike in Haemonetics Stock?

Haemonetics Corporation (HAE) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Videos

No Data

Press releases

Pharvaris Announces Annual General Meeting of Shareholders

Haemonetics Updates Financial Reporting Segments

Haemonetics Corporation Announces Fourth Quarter Fiscal 2026 Financial Results Available on Investor Relations Website

New Study Highlights Safety and Efficacy Profile of Haemonetics' VASCADE MVP® XL in Large-Bore Venous Access Closure Procedures